INTRODUCTION:Diabetes is a major risk factor for Alzheimer's disease (AD), and both diseases involve mitochondrial dysfunction. We hypothesised that AD is associated with reduced mitochondrial DNA copy number (mtDNA-CN) in vulnerable brain regions, and that diabetes modifies these changes. METHODS:Post-mortem hippocampus, amygdala, and cerebellum samples (N=66-77) from non-cognitively impaired (NCI) and AD donors, with and without diabetes, were analysed. mtDNA-CN was quantified by absolute quantification. RESULTS:Overall, mtDNA-CN was lower in AD. However, stratification by diabetes revealed opposite changes: non-diabetic AD cases showed reduced mtDNA-CN, whereas diabetic cases showed higher mtDNA-CN across all regions irrespective of cognitive status. DISCUSSION:These findings confirm multiregional loss of mtDNA-CN in the AD brain, most evident in the absence of diabetes. The functional significance of higher mtDNA-CN in the diabetic brain remains unclear, but evidence that diabetes can mask effects has important implications for dementia studies.

Acute brain injury is difficult to evaluate in veterinary medicine and tools to investigate the potential involvement of mitochondrial involvement are limited. The brain is highly enriched in mitochondria and contains thousands of copies of mitochondrial DNA (mtDNA) per cell, but robust methods for quantifying mitochondrial DNA copy number (mtDNA-CN) in canine tissues are lacking. We describe the development of a quantitative real-time PCR assay for absolute measurement of mtDNA-CN which was validated in canine blood and brain tissue. To minimize amplification of nuclear mitochondrial insertion sequences (NumtS) and repetitive regions, species-specific oligonucleotide primers were designed following in silico genomic filtering. The assay was applied to a small pilot cohort comprising blood samples from dogs with and without acute brain injury (n = 4-6 per group) and cerebral cortex samples (n = 1 per group) to assess feasibility and biological plausibility. In non-brain injury dogs, blood mtDNA-CN ranged from 98 to 288 copies per nuclear genome (mean 193 ± 72), while values in brain-injured cases ranged from 163 to 228 copies per genome (mean 200 ± 33). Cerebral cortex samples exhibited higher mtDNA-CN than blood, consistent with known tissue-specific mitochondrial enrichment. In a single brain-injured case with serial sampling, mtDNA-CN increased over five days. This study presents a validated assay and pilot data for mtDNA-CN quantification in canine samples. While not powered for biomarker evaluation, this method may enable future studies of mitochondrial dynamics in canine brain injury and metabolic disease.

Acute brain injury is challenging to manage in veterinary medicine, with limited validated means of prognostication currently available. The brain is rich in mitochondrial content and contains thousands of copies of mitochondrial DNA (mtDNA) per cell. We hypothesized that brain cell loss following acute brain injury may result in release of mtDNA into the systemic circulation. To investigate this, mtDNA-CN was measured in blood (n=4-6/group) and cerebral cortex (n=1/group) samples from dogs with and without brain injury using absolute quantification by real-time qPCR. By filtering out regions with homology to nuclear mitochondrial insertion sequences (NumtS) and repetitive regions, oligonucleotide primers were designed to the canine mitochondrial and nuclear genomes. In controls, blood mtDNA-CN ranged from 98 to 288 (mean 193±72), in cases of brain injury, there was a non-significant trend for higher mtDNA-CN, ranging from 163-453 (mean 244±106). As expected, cerebral cortex contained higher mtDNA-CN than the blood. In a single case with serial sampling, mtDNA-CN increased five days post-injury. We present for the first time an assay to accurately quantify mtDNA-CN in canine samples, with potential as a biomarker for acute brain injury in veterinary practice. This work describes a novel assay to accurately measure absolute levels of canine mitochondrial DNA copy number (mtDNA-CN) in biological samples. We describe the range of mtDNA-CN in canine blood and show pilot data suggesting that blood mtDNA-CN should be evaluated as a potential biomarker of acute brain injury.

Diabetes increases the risk of Alzheimer’s disease (AD), and mitochondrial dysfunction is implicated in both diseases. We previously detected mitochondrial DNA copy number (MtDNA-CN) changes in human parietal cortex that differed between diabetic AD and non-diabetic AD. We hypothesize that MtDNA-CN changes may be indicative of different underlying mechanisms. In the current study, we aim to evaluate the impact of MtDNA-CN changes on MtDNA damage and proteins involved in energy production in the mitochondria. Total DNA and protein were isolated from human post-mortem parietal cortex (n = 24). MtDNA-CN was determined as the ratio of MtDNA to nuclear DNA using qPCR. MtDNA damage was measured using the surveyor nuclease method in 11 overlapping mitochondrial genome regions, and next generation sequencing (NGS) after removing the nuclear DNA using exonuclease V. NDUFB8(I), SDHB(II), UQCRC2(III), MTCO1(IV), and ATP5A(V) expression were measured as the representatives of 5 complexes in OXPHOS chain by western blotting. Data were compared as 4 groups: non-cognitive impairment (NCI) and AD, ± diabetes using ANOVA. In AD groups, MtDNA-CN was reduced in cases without diabetes (P<0.05), however, no reduction was seen in diabetic AD. In diabetic groups, irrespective of cognitive status, higher MtDNA-CN were found compared to non-diabetic groups. Putative mutations with various intensities and patterns were observed, especially in the displacement loop area in AD and diabetic AD groups. Among 4 groups, the expression of 2 nuclear-encoded subunits NDUFB8 and ATP5A were higher than the level of other 2 nuclear-encoded subunits (SDHB and UQCRC2) and 1 mitochondrial-encoded subunit MTCO1. However, no significant difference was found in the expression of these 5 subunits between diabetic and non-diabetic groups in parietal cortex. Our data show that in human parietal cortex, the MtDNA-CN changes differently in diabetic and non-diabetic AD suggesting of different underlying mechanisms. The presence of MtDNA changes without any impact on levels of OXPHOS subunits indicates an MtDNA-based pathology. We propose that different patterns of MtDNA damage may impact energy production in specific brain regions and contribute to disease progression. The level of MtDNA heteroplasmy in the groups determined by NGS and its potential impact will be presented.

Abstract Background We previously reported aberrant expression of the cytosolic ribosomal biogenesis factor Nop-7-associated 2 (NSA2) in diabetic nephropathy, the latter also known to involve mitochondrial dysfunction, however the connections between NSA2, mitochondria and renal disease were unclear. In the current paper, we show that NSA2 expression is co-regulated with the GTP-dependent ribosome recycling factor mitochondrial 2 (GFM2) and provide a molecular link between cytosolic and mitochondrial ribosomal biogenesis with mitochondrial dysfunction in chronic kidney disease (CKD). Methods Human renal tubular cells (HK-2) were cultured (+/- zinc, or 5mM/20mM glucose). mRNA levels were quantified using real-time qPCR. Transcriptomics data were retrieved and analysed from Nakagawa chronic kidney disease (CKD) Dataset (GSE66494) and Kidney Precision Medicine Project (KPMP) (https://atlas.kpmp.org/). Protein levels were determined by immunofluorescence and Western blotting. Cellular respiration was measured using Agilent Seahorse XF Analyzer. Data were analysed using one-way ANOVA, Students’ t-test and Pearson correlation. Results The NSA2 gene, on human chromosome 5q13 was next to GFM2. The two genes were syntenic on opposite strands and orientation in multiple species. Their common 381 bp 5’ region contained multiple transcription factor binding sites (TFBS) including the zinc-responsive transcription factor MTF1. NSA2 and GFM2 mRNAs showed a dose-dependent increase to zinc in-vitro and were highly expressed in proximal tubular cells in renal biopsies. CKD patients showed higher renal NSA2/GFM2 expression. In HK-2 cells, hyperglycaemia led to increased expression of both genes. The total cellular protein content remained unchanged, but GFM2 upregulation resulted in increased levels of several mitochondrial oxidative phosphorylation (OXPHOS) subunits. Furthermore, increased GFM2 expression, via transient transfection or hyperglycemia, correlated with decrease cellular respiration. Conclusion The highly conserved synteny of NSA2 and GFM2, their shared 5’ region, and co-expression in-vitro and in CKD, shows they are co-regulated. Increased GFM2 affects mitochondrial function with a disconnect between an increase in certain mitochondrial respiratory proteins but a decrease in cellular respiration. These data link the regulation of 2 highly conserved genes, NSA2 and GFM2, connected to ribosomes in two different cellular compartments, cytosol and mitochondria, to kidney disease and shows that their dysregulation may be involved in mitochondrial dysfunction.

PURPOSE OF REVIEW:MtDNA copy number (CN), a putative noninvasive biomarker of mitochondrial dysfunction, is associated with renal disease. The purpose of this review is to describe studies which measured human blood mtDNA-CN in the context of chronic kidney disease (CKD), and to evaluate its potential as a clinical biomarker of kidney disease. RECENT FINDINGS:Following on from small scale cross-sectional studies implicating mtDNA-CN changes in diabetic kidney disease, recent large scale population studies provide compelling evidence of the association of mtDNA-CN and risk of renal disease in the general population and poor outcomes in CKD patients. SUMMARY:The kidney has high bioenergetic needs, renal cells are rich in mitochondrial content containing 100s to 1000s of mtDNA molecular per cell. MtDNA has emerged as both a potential mediator, and a putative biomarker of renal disease. Damage to mtDNA can result in bioenergetic deficit, and reduced MtDNA levels in the blood have been shown to correlate with CKD. Furthermore, leakage of mtDNA outside of mitochondria into the cytosol/periphery can directly cause inflammation and is implicated in acute kidney injury (AKI). Recent large-scale population studies show the association of mtDNA-CN and renal disease and provide a strong basis for the future evaluation of circulating DNA-CN in longitudinal studies to determine its utility as a clinical biomarker for monitoring renal function.

Macromolecules of various sizes induce crowding of the cellular environment. This crowding impacts on biochemical reactions by increasing solvent viscosity, decreasing the water-accessible volume and altering protein shape, function, and interactions. Although mitochondria represent highly protein-rich organelles, most of these proteins are somehow immobilized. Therefore, whether the mitochondrial matrix solvent exhibits macromolecular crowding is still unclear. Here, we demonstrate that fluorescent protein fusion peptides (AcGFP1 concatemers) in the mitochondrial matrix of HeLa cells display an elongated molecular structure and that their diffusion constant decreases with increasing molecular weight in a manner typical of macromolecular crowding. Chloramphenicol (CAP) treatment impaired mitochondrial function and reduced the number of cristae without triggering mitochondrial orthodox-to-condensed transition or a mitochondrial unfolded protein response. CAP-treated cells displayed progressive concatemer immobilization with increasing molecular weight and an eightfold matrix viscosity increase, compatible with increased macromolecular crowding. These results establish that the matrix solvent exhibits macromolecular crowding in functional and dysfunctional mitochondria. Therefore, changes in matrix crowding likely affect matrix biochemical reactions in a manner depending on the molecular weight of the involved crowders and reactants.

Chemotherapy-induced peripheral neuropathy (CIPN) is a serious dose-limiting side effect of several first-line chemotherapeutic agents including paclitaxel, oxaliplatin and bortezomib, for which no predictive marker is currently available. We have previously shown that mitochondrial dysfunction is associated with the development and maintenance of CIPN. The aim of this study was to evaluate the potential use of mitochondrial DNA (mtDNA) levels and complex I enzyme activity as blood biomarkers for CIPN. Real-time qPCR was used to measure mtDNA levels in whole blood collected from chemotherapy- and vehicle-treated rats at three key time-points of pain-like behaviour: prior to pain development, at the peak of mechanical hypersensitivity and at resolution of pain-like behaviour. Systemic oxaliplatin significantly increased mtDNA levels in whole blood prior to pain development. Furthermore, paclitaxel- and bortezomib-treated animals displayed significantly higher levels of mtDNA at the peak of mechanical hypersensitivity. Mitochondrial complex I activity in whole blood was assessed with an ELISA-based Complex I Enzyme Activity Dipstick Assay. Complex I activity was not altered by any of the three chemotherapeutic agents, either prior to or during pain-like behaviour. These data demonstrate that blood levels of mtDNA are altered after systemic administration of chemotherapy. Oxaliplatin, in particular, is associated with higher mtDNA levels before animals show any pain-like behaviour, thus suggesting a potential role for circulating mtDNA levels as non-invasive predictive biomarker for CIPN.

Protein lateral diffusion is considered anomalous in the plasma membrane. And this diffusion is related to membrane microstructure. In order to better describe the property of protein lateral diffusion and find out the inner relationship between protein lateral diffusion and membrane microstructure, this article applies variable-order fractional mean square displacement (f-MSD) function for characterizing the anomalous diffusion. It is found that the variable order can reflect the evolution of diffusion ability. The results of numerical simulation demonstrate variable-order f-MSD function can predict the tendency of anomalous diffusion during the process of confined diffusion. It is also noted that protein lateral diffusion ability during the processes of confined and hop diffusion can be split into three parts. In addition, the comparative analyses reveal that the variable order is related to the confinement-domain size and microstructure of compartment boundary too.

Changes in circulating mitochondrial DNA (mtDNA) are widely used to indicate mitochondrial dysfunction in common non-genetic diseases where mitochondrial dysfunction may play a role. However, the methodology being used is not always specific and reproducible, and most studies use whole blood rather than evaluating cellular and cell-free mtDNA separately. Cellular mtDNA is contained within the mitochondrion and encodes vital subunits of the OXPHOS machinery. Conversely, cell-free mtDNA can have harmful effects, triggering inflammatory responses and potentially contributing to pathogenic processes. In this chapter, we describe a protocol to accurately measure the amount of cellular and cell-free human mtDNA in peripheral blood. Absolute quantification is carried out using real-time quantitative PCR (qPCR) to quantify cellular mtDNA, measured as the mitochondrial genome to nuclear genome ratio (designated the Mt/N ratio) in whole blood and peripheral blood mononuclear cells (PBMCs) and the number of mtDNA copies per μL in plasma and serum. We describe how to (1) separate whole blood into PBMCs, plasma, and serum fractions, (2) prepare DNA from each of these fractions, (3) prepare dilution standards for absolute quantification, (4) carry out qPCR for either relative or absolute quantification from test samples, (5) analyze qPCR data, and (6) calculate the sample size to adequately power studies. The protocol presented here is suitable for high-throughput use and can be modified to quantify mtDNA from other body fluids, human cells, and tissues.

According to the 'multiple-hit' hypothesis, several factors can act simultaneously in nonalcoholic fatty liver disease (NAFLD) progression. Increased nitro-oxidative (nitroso-oxidative) stress may be considered one of the main contributors involved in the development and risk of NAFLD progression to nonalcoholic steatohepatitis (NASH) characterized by inflammation and fibrosis. Moreover, it has been repeatedly postulated that mitochondrial abnormalities are closely related to the development and progression of liver steatosis and NAFLD pathogenesis. However, it is difficult to determine with certainty whether mitochondrial dysfunction or oxidative stress are primary events or a simple consequence of NAFLD development. On the one hand, increasing lipid accumulation in hepatocytes could cause a wide range of effects from mild to severe mitochondrial damage with a negative impact on cell fate. This can start the cascade of events, including an increase of cellular reactive nitrogen species (RNS) and reactive oxygen species (ROS) production that promotes disease progression from simple steatosis to more severe NAFLD stages. On the other hand, progressing mitochondrial bioenergetic catastrophe and oxidative stress manifestation could be considered accompanying events in the vast spectrum of abnormalities observed during the transition from NAFL to NASH and cirrhosis. This review updates our current understanding of NAFLD pathogenesis and clarifies whether mitochondrial dysfunction and ROS/RNS are culprits or bystanders of NAFLD progression.

Objectives We hypothesised that maternal diet-induced-obesity has adverse consequences for offspring energy expenditure and susceptibility to obesity in adulthood, and that the prebiotic polydextrose (PDX) would prevent the consequences of programming by maternal obesity. Methods Female mice were fed a control (Con) or obesogenic diet (Ob) for 6 weeks prior to mating and throughout pregnancy and lactation. Half the obese dams were supplemented with 5% PDX (ObPDX) in drinking water throughout pregnancy and lactation. Offspring were weaned onto standard chow. At 3 and 6 months, offspring energy intake (EI) and energy expenditure (EE by indirect calorimetry) were measured, and a glucose-tolerance test performed. Offspring of control (OffCon), obese (OffOb) and PDX supplemented (OffOb P ) dams were subsequently challenged for 3 weeks with Ob, and energy balanced reassessed. Potential modifiers of offspring energy balance including gut microbiota and biomarkers of mitochondrial activity were also evaluated. Results Six-month-old male OffOb demonstrated increased bodyweight (BW, P < 0.001) and white adipose tissue mass ( P < 0.05), decreased brown adipose tissue mass (BAT, P < 0.01), lower night-time EE ( P < 0.001) versus OffCon, which were prevented in OffOb P . Both male and female OffOb showed abnormal glucose-tolerance test (peak [Glucose] P < 0.001; AUC, P < 0.05) which was prevented by PDX. The Ob challenge resulted in greater BW gain in both male and female OffOb versus OffCon ( P < 0.05), also associated with increased EI ( P < 0.05) and reduced EE in females ( P < 0.01). OffOb P were protected from accelerated BW gain on the OB diet compared with controls, associated with increased night-time EE in both male ( P < 0.05) and female OffOb P ( P < 0.001). PDX also prevented an increase in skeletal muscle mtDNA copy number in OffOb versus OffCon ( P < 0.01) and increased the percentage of Bacteroides cells in faecal samples from male OffOb P relative to controls. Conclusions Maternal obesity adversely influences adult offspring energy balance and propensity for obesity, which is ameliorated by maternal PDX treatment with associated changes in gut microbiota composition and skeletal muscle mitochondrial function.

Pretransplant islet culture is associated with the loss of islet cell mass and insulin secretory function. Insulin secretion from islet β-cells is primarily controlled by mitochondrial ATP generation in response to elevations in extracellular glucose. Coculture of islets with mesenchymal stromal cells (MSCs) improves islet insulin secretory function in vitro, which correlates with superior islet graft function in vivo. This study aimed to determine whether the improved islet function is associated with mitochondrial transfer from MSCs to cocultured islets. We have demonstrated mitochondrial transfer from human adipose MSCs to human islet β-cells in coculture. Fluorescence imaging showed that mitochondrial transfer occurs, at least partially, through tunneling nanotube (TNT)-like structures. The extent of mitochondrial transfer to clinically relevant human islets was greater than that to experimental mouse islets. Human islets are subjected to more extreme cellular stressors than mouse islets, which may induce "danger signals" for MSCs, initiating the donation of MSC-derived mitochondria to human islet β-cells. Our observations of increased MSC-mediated mitochondria transfer to hypoxia-exposed mouse islets are consistent with this and suggest that MSCs are most effective in supporting the secretory function of compromised β-cells. Ensuring optimal MSC-derived mitochondria transfer in preculture and/or cotransplantation strategies could be used to maximize the therapeutic efficacy of MSCs, thus enabling the more widespread application of clinical islet transplantation.

Executive summary – Box 1: In brief: Mitochondria and bioblasts .......................................... 2 1. Introduction ............................................................................................................................................................................. 8 2. Coupling states and rates in mitochondrial preparations ................................................................................... 8 2.1. Cellular and mitochondrial respiration ................................................................................................................. 8 2.1.1. Aerobic and anaerobic catabolism and ATP turnover Consortium Communication 2 of 44 Gnaiger E et al ― MitoEAGLE Task Group (2020) Bioenerg Commun 2020.1 2.1.2. Specification of biochemical dose and exposure 2.2. Mitochondrial preparations .................................................................................................................................... 10 2.3. Electron transfer pathways ..................................................................................................................................... 11 2.4. Respiratory coupling control .................................................................................................................................. 12 2.4.1. Coupling 2.4.2. Phosphorylation P» and P»/O2 ratio 2.4.3. Uncoupling 2.5. Coupling states and respiratory rates ................................................................................................................. 13 2.5.1. LEAK state 2.5.2. OXPHOS state 2.5.3. Electron transfer state 2.5.4. ROX state 2.5.5. Quantitative relations 2.5.6. The steady state 2.6. Classical terminology for isolated mitochondria ............................................................................................ 19 2.6.1. – 2.6.5. State 1 – State 5 2.7. Control and regulation .............................................................................................................................................. 21 3. What is a rate? – Box 2: Metabolic flows and fluxes: vectoral, vectorial, and scalar ............................. 21 4. Normalization of rate per sample................................................................................................................................. 23 4.1. Flow: per object ............................................................................................................................................................ 23 4.1.1. Count concentration 4.1.2. Flow per single object 4.2. Size-specific flux: per sample size .......................................................................................................................... 25 4.2.1. Mass concentration 4.2.2. Size-specific flux 4.3. Marker-specific flux: per mitochondrial content ............................................................................................. 26 4.3.1. Mitochondrial concentration and mitochondrial density 4.3.2. mt-Marker-specific flux 5. Normalization of rate per system ................................................................................................................................ 28 5.1. Flow: per chamber ...................................................................................................................................................... 28 5.2. Flux: per chamber volume ....................................................................................................................................... 28 5.2.1. System-specific flux 5.2.2. Advancement per volume 6. Conversion of units ............................................................................................................................................................ 30 7. Conclusions – Box 3: Recommendations for studies with mitochondrial preparations ...................... 31 References ............................................................................................................................................................................. 36 Authors (MitoEAGLE Task Group) – Author contributions .............................................................................. 41 Acknowledgements – Competing financial interests – Correspondence

Circulating mitochondrial DNA (mtDNA), widely studied as a disease biomarker, comprises of mtDNA located within mitochondria, indicative of mitochondrial function, and cell-free (cf) mtDNA linked to inflammation. The purpose of this study was to determine the ranges of, and relationship between, cellular and cf mtDNA in human blood. Whole blood from 23 controls (HC) and 20 patients with diabetes was separated into peripheral blood mononuclear cells (PBMCs), plasma, and serum. Total DNA was isolated and mtDNA copy numbers were determined using absolute quantification. Cellular mtDNA content in PBMCs was higher than in peripheral blood and a surprisingly high level of cf mtDNA was present in serum and plasma of HC, with no direct relationship between cellular and cf mtDNA content within individuals. Diabetes patients had similar levels of cellular mtDNA compared to healthy participants but a significantly higher cf mtDNA content. Furthermore, only in patients with diabetes, we observed a correlation between whole blood and plasma mtDNA levels, indicating that the relationship between cellular and cf mtDNA content is affected by disease status. In conclusion, when evaluating mtDNA in human blood as a biomarker of mitochondrial dysfunction, it is important to measure both cellular and cf mtDNA.